{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}],"title":"BICR: Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"28"}]}],"title":"BICR: Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"91"}]}],"title":"BICR: Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"41"}]}],"title":"BICR: Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"22"}]}],"title":"BICR: Not evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}],"title":"Investigator: Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"31"}]}],"title":"Investigator: Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"93"}]}],"title":"Investigator: Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"40"}]}],"title":"Investigator: Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}],"title":"Investigator: Not evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"30"}]}],"title":"BICR: Confirmed Objective response rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"31"}]}],"title":"Investigator: Confirmed Objective response rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.","groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"OG001","title":"Physician's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Best overall response and confirmed objective response rate were assessed in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years","title":"Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)","type":"SECONDARY","unitOfMeasure":"Participants"}